Oncology

FDA grants fast track status for Full-Life’s prostate cancer treatment

The US Food and Drug Administration (FDA) has granted fast track designation for radiotherapeutics company Full-Life Technologies’ 225Ac-FL-020 to treat metastatic castration-resistant prostate cancer (mCRPC).

FDA grants Fast Track designation to Tubulis’ TUB-040 for ovarian cancer treatment

Tubulis has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead antibody-drug conjugate (ADC), TUB-040, aimed at treating patients with platinum-resistant ovarian cancer.

Yellowstone Biosciences launches to develop soluble bispecific cancer therapies

UK-based Yellowstone Biosciences has announced its launch with a £16.5m investment from Syncona to develop soluble bispecific T-cell receptor (TCR)-based therapies.

Iambic secures $50m to bolster clinical oncology programme pipeline

Clinical-stage biotechnology company Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising artificial intelligence (AI)-discovered clinical oncology programmes.

Takeda, Ascentage Pharma sign option agreement for olverembatinib

Takeda has entered into an option agreement with Ascentage Pharma, securing the opportunity to obtain exclusive global licensing rights for olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI).

Sibylla Biotech, MD Anderson to develop cancer treatments

Sibylla Biotech has entered into a strategic partnership with The University of Texas MD Anderson Cancer Center to advance the development of new cancer therapies.

Repare Therapeutics secures FDA Fast Track designation for ovarian cancer therapy

Repare Therapeutics has received Fast Track designation from the US Food and Drug Administration (FDA) for lunresertib in combination with camonsertib to treat adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A-mutated platinum-resistant ovarian cancer.

ImmunoACT and Caring Cross sign TriCAR-T cell therapy development deal

India-based ImmunoAdoptive Cell Therapy (ImmunoACT) has entered into a partnership with Caring Cross to advance the development and commercialisation of a Tri-functional chimeric antigen receptor (TriCAR)-T cell immunotherapy aimed at treating leukaemia and lymphoma.

OverT Bio secures $16m in seed funding for cell therapy development

Data-driven biotechnology company OverT Bio has secured $16m in a seed funding round to expand its discovery platforms aimed at developing cellular therapies for solid tumours.